PMC7161089_01
PMC7161089_02
PMC7161089_03
Hematology parameters in dynamics for the patients. Case 2: At diagnosis: KRAS G13D mutation with 21% variant allele frequency (VAF). Molecular monitoring by NGS after 3 courses of therapy indicated a decrease of mutational load to 12%. Molecular monitoring by NGS after 8 courses of therapy indicated complete molecular remission. After HSCT: complete molecular remission. Case 3: At diagnosis: KRAS G13D mutation with a VAF of 38%. Molecular monitoring by NGS after 3 courses of therapy: mutational load 37.5%. Molecular monitoring by NGS at the end of therapy: VAF 35.2%. After HSCT: VAF 2.5%.
fonc-10-00484-g0001.jpg
PMC7161089_03_fonc-10-00484-g0001.jpg
F1
No hematologic toxicities were reported in our series (Figure 1).